Cryoport FY2025 revenue $176.2M (+12% YoY) beats guidance; FY2026 outlook $190-194M

Cryoport, Inc.

FY2025 revenue $176.2M, up 12% YoY; Q4 revenue $45.5M, up 10% YoY.
Loss from continuing operations $34.0M; adjusted EBITDA from cont. ops -$5.8M (vs -$17.8M).
Commercial cell & gene therapy revenue $33.4M (+29% YoY); supported 760 clinical trials.
Life Sciences Services revenue $96.5M (+18%); BioStorage/BioServices up 22% to $18.4M.
Cash & investments $411.2M; repurchased 1.34M shares at avg $7.45 for $10.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.